查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1965347

循环性肿瘤细胞市场－全球产业规模、份额、趋势、机会、预测：按产品、技术、地区和竞争对手划分，2021-2031年

Circulating Tumor Cells Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Technology, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球循环性肿瘤细胞市场预计将从 2025 年的 70.6 亿美元成长到 2031 年的 109.4 亿美元，复合年增长率为 7.57%。

该市场专注于从原发肿瘤脱落并进入血液的癌细胞，这些癌细胞可作为重要的生物标记物，用于监测转移进展和治疗效果。市场成长的主要驱动力是全球癌症负担的日益加重以及对非侵入性液态生物检体诊断需求的增长。美国癌症协会 (ACS) 估计，到 2025 年，美国将新增 2,041,910 例癌症病例，凸显了对有效疾病管理工具的迫切需求。此外，无需手术干预即可进行频繁的患者评估的能力也持续推动着该行业的成长。

市场概览
预测期 2027-2031
市场规模：2025年 70.6亿美元
市场规模：2031年 109.4亿美元
复合年增长率：2026-2031年 7.57%
成长最快的细分市场 试剂盒和试剂
最大的市场 北美洲

然而，市场面临一项重大挑战：细胞分离技术缺乏标准化。血液样本中这些细胞的浓度极低，导致不同平台间检测结果的一致性和可重复性难以保证。这种技术复杂性需要昂贵的设备和专门的处理方法，从而导致高昂的营运成本，限制了其在临床上的应用以及在标准医疗体系中的报销。

市场驱动因素

微流体和晶片分离技术的进步正在改变市场格局，解决了血液样本中细胞浓度过低这一关键瓶颈。这些专用平台能够捕捉和收集无标定的循环性肿瘤细胞，从而实现以往依赖上皮标记的方法无法进行的下游分析。这些创新技术的商业性成功体现在系统应用范围的扩大。例如，根据 Alliance News 2025 年 1 月报道，Angle 公司 2024 年全年营收成长至 290 万英镑，这主要得益于 Parsortix液态生物检体系统在製药服务和临床领域的广泛应用。这种向高灵敏度浓缩工具的转变使临床医生能够更精确地监测肿瘤转移的可能性，从而直接改善患者管理策略并推动市场成长。

同时，公共和私人机构对癌症研究投入的增加，正加速液态生物检体技术从学术研究到常规临床实践的转化。各国政府和主要医疗机构认识到紧急应变，并正大力投资于大规模研究，以检验循环肿瘤细胞（CTC）生物标记在早期检测和治疗方案中的应用。欧盟委员会强调了这种临床紧迫性，并在2025年12月估计，2024年欧盟成员国将新增约270万例癌症病例，将对可扩展的诊断解决方案产生巨大需求。为此，津贴已拨款开发新的调查方法。特别是，根据GenomeWeb在2025年5月报道，奥斯陆大学医院获得了欧盟1360万欧元的津贴，用于开发和检验针对遗传性癌症综合征的液态生物检体检测方法。

市场挑战

细胞分离技术缺乏标准化仍是全球循环性肿瘤细胞循环性肿瘤细胞(CTC) 市场成长的主要障碍。由于 CTC 在血液样本中的浓度极低，其检测需要复杂且高度灵敏的设备，且不同製造商的调查方法往往存在差异。这种技术上的不一致导致不同实验室间结果的差异以及可重复性的降低，使得肿瘤科医生难以像使用成熟的组织切片检查那样，可靠地将 CTC 作为重要治疗决策的依据。因此，这种差异性对监管机构的检验和医学界的认可构成了重大障碍。

这些技术挑战直接导致营运成本飙升，进一步阻碍了市场扩张。分离这些稀有细胞所需的专用设备和劳动密集型工作流程推高了每次检测的成本，使得广泛的保险覆盖变得困难。美国癌症协会预测，到2025年，美国将有约618,120人死于癌症，凸显了先进监测工具的紧迫感。然而，儘管临床负担如此沉重，健康保险公司和保险机构仍然不愿采用昂贵且非标准化的循环肿瘤细胞（CTC）检测，这限制了其在标准临床实践中的应用，并限制了市场盈利能力。

市场趋势

人工智慧驱动的循环肿瘤细胞（CTC）自动化检测技术的整合，从根本上改变了市场格局，克服了从数十亿血细胞中识别罕见癌细胞这一长久以来的难题。先进的机器学习演算法被引入高内涵影像分析，显着提高了检测灵敏度，并减少了人工操作偏差造成的差异。这项技术飞跃实现了工作流程的标准化和高通量，直接解决了阻碍临床应用的可扩展性问题。 2024年5月发表于《临床肿瘤学杂誌》（Journal of Clinical Oncology）的一篇文章也印证了这项进展。该文章报告了一项使用自动化深度学习模型进行循环性肿瘤细胞分析的研究，其检测准确率约为96.66%，凸显了人工智慧在提供常规诊断应用所需可靠性方面的潜力。

同时，肿瘤检测产业正经历从简单的细胞计数到分子表型分析的关键转变，并逐步发展成为能够表征细胞生物学特性的精准医疗。临床医生和研究人员不仅关注转移负荷的评估，还致力于分析分离细胞的蛋白质组学和基因组学特征，以识别特定的治疗标靶和抗药性机制。这种对更深入生物学洞察的追求正推动着大量投资，以支持下一代表征工具的发展。例如，2024年6月，RareCyte成功完成了2,000万美元的资金筹措，旨在扩展其精准生物学平台。该平台能够实现对单一循环性肿瘤细胞的可见回收和分子分析。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球循环性肿瘤细胞市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依产品类型（试剂盒/试剂、采血管、设备或系统）
    • 按技术（CTC检测与浓缩方法、CTC直接检测方法、CTC分析）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美循环性肿瘤细胞市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：循环性肿瘤细胞的欧洲市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区循环性肿瘤细胞市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲循环性肿瘤细胞市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲循环性肿瘤细胞市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章 全球循环性肿瘤细胞市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • QIAGEN NV
  • Bio-Techne Corp.
  • Precision Medicine Group, LLC
  • Bio-Rad Laboratories, Inc.
  • Natera, Inc.
  • Illumina, Inc.
  • Greiner Bio-One International GmbH
  • Ikonisys Inc.
  • Creative Bioarray
  • Abnova Corporation

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 15903

The Global Circulating Tumor Cells Market to expand from USD 7.06 Billion in 2025 to USD 10.94 Billion by 2031 with a CAGR of 7.57%. The Global Circulating Tumor Cells Market is centered on cancer cells that detach from primary tumors and enter the bloodstream, serving as vital biomarkers for metastatic progression and therapeutic monitoring. The market is primarily propelled by the rising global cancer burden and the increasing preference for non-invasive liquid biopsy diagnostics. According to the American Cancer Society, an estimated 2,041,910 new cancer cases were projected to be diagnosed in the United States in 2025, underscoring the critical need for effective disease management tools. Additionally, the capability to conduct frequent patient assessments without the risks linked to surgical interventions continues to support industry growth.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 7.06 Billion
Market Size 2031USD 10.94 Billion
CAGR 2026-20317.57%
Fastest Growing SegmentKits & Reagents
Largest MarketNorth America

However, the market faces a substantial hurdle regarding the lack of standardization in cell isolation technologies. The extremely low abundance of these cells in blood samples makes consistent detection and reproducibility difficult across different platforms. This technical complexity demands expensive instrumentation and specialized processing, resulting in high operational costs that restrict widespread clinical adoption and reimbursement within standard healthcare systems.

Market Driver

Technological advancements in microfluidic and chip-based isolation are transforming the market by resolving the critical bottleneck of low cell abundance in blood samples. These specialized platforms now allow for the label-free capture and harvesting of intact circulating tumor cells, enabling downstream analysis that was previously unachievable with older epithelial marker-dependent methods. The commercial success of these innovations is reflected in the rising adoption of such systems; for instance, according to Alliance News in January 2025, Angle plc reported that its full-year 2024 revenue rose to £2.9 million, driven by the increased deployment of its Parsortix liquid biopsy system in pharma services and clinical settings. This move toward high-sensitivity enrichment tools permits clinicians to perform longitudinal monitoring of metastatic potential with greater precision, directly improving patient management strategies and fueling market growth.

Simultaneously, the increase in public and private funding for oncology research is accelerating the transition of liquid biopsy technologies from academic labs to routine clinical practice. Governments and major health organizations are investing heavily in large-scale studies to validate CTC biomarkers for early detection and treatment selection, acknowledging the urgent need to tackle the growing cancer burden. This clinical urgency was highlighted by the European Commission, which noted in December 2025 that there were approximately 2.7 million new cancer cases estimated across EU Member States in 2024, creating a massive demand for scalable diagnostic solutions. In direct response, substantial financial grants are being awarded to pioneer new methodologies; notably, according to GenomeWeb in May 2025, Oslo University Hospital received a €13.6 million European Union grant specifically to develop and validate liquid biopsy tests for hereditary cancer syndromes.

Market Challenge

The absence of standardization in cell isolation technologies remains a significant impediment to the growth of the Global Circulating Tumor Cells Market. Since circulating tumor cells (CTCs) are present in extremely low abundance within blood samples, detecting them requires complex, highly sensitive instrumentation that often varies in methodology across different manufacturers. This technical inconsistency leads to variable and irreproducible results between laboratories, making it challenging for oncologists to rely on CTCs for critical treatment decisions with the same confidence as established tissue biopsies. Consequently, this variability creates a substantial barrier to regulatory validation and acceptance by the broader medical community.

These technical challenges directly contribute to prohibitive operational costs, further hampering market expansion. The specialized equipment and labor-intensive workflows required to isolate these rare cells drive up the price per test, creating a difficult environment for widespread reimbursement. According to the American Cancer Society, in 2025, an estimated 618,120 cancer deaths were projected to occur in the United States, emphasizing the urgent need for advanced monitoring tools. However, despite this immense clinical burden, healthcare payers and insurance providers remain hesitant to cover expensive, non-standardized CTC assays, thereby limiting their adoption in standard clinical practice and restricting the market's revenue potential.

Market Trends

The integration of Artificial Intelligence for Automated CTC Detection is fundamentally reshaping the market by overcoming the historical challenge of identifying rare tumor cells amidst billions of blood cells. Advanced machine learning algorithms are now being deployed to analyze high-content images, significantly improving detection sensitivity and reducing the variability associated with manual operator bias. This technological leap allows for the standardization of workflows and higher throughput, directly addressing the scalability issues that have hindered clinical adoption. Validating this progress, according to the Journal of Clinical Oncology in May 2024, a study utilizing automated deep learning models for circulating tumor cell analysis demonstrated a detection accuracy of approximately 96.66%, highlighting the potential of AI to deliver the reliability required for routine diagnostic use.

Concurrently, the industry is witnessing a decisive shift from simple enumeration to molecular phenotyping, moving beyond merely counting cells to characterizing their biological properties for precision medicine. Clinicians and researchers are increasingly focused on analyzing the proteomic and genomic profiles of isolated cells to identify specific therapeutic targets and resistance mechanisms, rather than just assessing metastatic burden. This transition towards deeper biological insight is attracting significant investment to support the development of next-generation characterization tools. For instance, according to RareCyte, Inc. in June 2024, the company successfully completed a $20 million financing round specifically aimed at expanding its precision biology platform, which enables the visual retrieval and molecular profiling of single circulating tumor cells.

Key Market Players

  • QIAGEN N.V.
  • Bio-Techne Corp.
  • Precision Medicine Group, LLC
  • Bio-Rad Laboratories, Inc.
  • Natera, Inc.
  • Illumina, Inc.
  • Greiner Bio-One International GmbH
  • Ikonisys Inc.
  • Creative Bioarray
  • Abnova Corporation

Report Scope

In this report, the Global Circulating Tumor Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Circulating Tumor Cells Market, By Product

  • Kits & Reagents
  • Blood Collection Tubes
  • Devices or Systems

Circulating Tumor Cells Market, By Technology

  • CTC Detection & Enrichment Methods
  • CTC Direct Detection Methods
  • CTC Analysis

Circulating Tumor Cells Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Circulating Tumor Cells Market.

Available Customizations:

Global Circulating Tumor Cells Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Circulating Tumor Cells Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Kits & Reagents, Blood Collection Tubes, Devices or Systems)
    • 5.2.2. By Technology (CTC Detection & Enrichment Methods, CTC Direct Detection Methods, CTC Analysis)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Circulating Tumor Cells Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Technology
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Circulating Tumor Cells Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Technology
    • 6.3.2. Canada Circulating Tumor Cells Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Technology
    • 6.3.3. Mexico Circulating Tumor Cells Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Technology

7. Europe Circulating Tumor Cells Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Technology
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Circulating Tumor Cells Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Technology
    • 7.3.2. France Circulating Tumor Cells Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Technology
    • 7.3.3. United Kingdom Circulating Tumor Cells Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Technology
    • 7.3.4. Italy Circulating Tumor Cells Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Technology
    • 7.3.5. Spain Circulating Tumor Cells Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Technology

8. Asia Pacific Circulating Tumor Cells Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Technology
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Circulating Tumor Cells Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Technology
    • 8.3.2. India Circulating Tumor Cells Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Technology
    • 8.3.3. Japan Circulating Tumor Cells Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Technology
    • 8.3.4. South Korea Circulating Tumor Cells Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Technology
    • 8.3.5. Australia Circulating Tumor Cells Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Technology

9. Middle East & Africa Circulating Tumor Cells Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Technology
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Circulating Tumor Cells Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Technology
    • 9.3.2. UAE Circulating Tumor Cells Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Technology
    • 9.3.3. South Africa Circulating Tumor Cells Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Technology

10. South America Circulating Tumor Cells Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Technology
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Circulating Tumor Cells Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Technology
    • 10.3.2. Colombia Circulating Tumor Cells Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Technology
    • 10.3.3. Argentina Circulating Tumor Cells Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Technology

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Circulating Tumor Cells Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. QIAGEN N.V.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bio-Techne Corp.
  • 15.3. Precision Medicine Group, LLC
  • 15.4. Bio-Rad Laboratories, Inc.
  • 15.5. Natera, Inc.
  • 15.6. Illumina, Inc.
  • 15.7. Greiner Bio-One International GmbH
  • 15.8. Ikonisys Inc.
  • 15.9. Creative Bioarray
  • 15.10. Abnova Corporation

16. Strategic Recommendations

17. About Us & Disclaimer